Clinical Trials Directory

Trials / Completed

CompletedNCT02168738

Investigation of Docosahexaenoic Acid (DHA) Metabolic Pathway in Human by Using 13C Labeled Molecules

Bioavailability of DHA-TG (Docosahexaenoic Triglyceride), DHA-PC (Docosahexaenoic Phosphatidylcholine) and AcedoPC (1-acetyl-2-docosahexaenoic-glycerophosphocholine) in Human

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
4 (actual)
Sponsor
Hospices Civils de Lyon · Academic / Other
Sex
Male
Age
60 Years – 70 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to compare three lipidic forms of DHA in their metabolic pathway in human by using 13C labeled molecules. The circulating form of DHA plays a major role in his cerebral incorporation. The aim of this research is to confirm that some lipidic forms are best carriers for the cerebral incorporation in studying 13C-DHA distribution in plasma lipids and blood cells.

Conditions

Interventions

TypeNameDescription
DRUG13-C labeled AceDoPC-DHAEach subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C. The dose contains 50 mg 13C-DHA. The wash-out period is four months
DRUG13-C labeled TG-DHAEach subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C. The dose contains 50 mg 13C-DHA. The wash-out period is four months
DRUG13-C labeled PC-DHAEach subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C. The dose contains 50 mg 13C-DHA. The wash-out period is four months

Timeline

Start date
2014-03-01
Primary completion
2015-04-01
Completion
2015-04-01
First posted
2014-06-20
Last updated
2025-12-19

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02168738. Inclusion in this directory is not an endorsement.